These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

618 related items for PubMed ID: 18278185

  • 1. PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children.
    Kinik ST, Ozbek N, Yuce M, Yazici AC, Verdi H, Ataç FB.
    Thromb Haemost; 2008 Feb; 99(2):352-6. PubMed ID: 18278185
    [Abstract] [Full Text] [Related]

  • 2. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
    Kinik ST, Ataç FB, Verdi H, Cetintaş S, Sahin FI, Ozbek N.
    Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
    [Abstract] [Full Text] [Related]

  • 3. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance.
    Sartori MT, Vettor R, De Pergola G, De Mitrio V, Saggiorato G, Della Mea P, Patrassi GM, Lombardi AM, Fabris R, Girolami A.
    Thromb Haemost; 2001 Nov; 86(5):1161-9. PubMed ID: 11816701
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [TNF-alpha and carbohydrate and lipid parameters in overweight and obese children].
    Goral J.
    Ann Acad Med Stetin; 2008 Nov; 54(2):14-21. PubMed ID: 19374226
    [Abstract] [Full Text] [Related]

  • 8. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity.
    Hoffstedt J, Andersson IL, Persson L, Isaksson B, Arner P.
    Diabetologia; 2002 Apr; 45(4):584-7. PubMed ID: 12032637
    [Abstract] [Full Text] [Related]

  • 9. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y, Murata M, Isshiki I, Watanabe R, Zama T, Watanabe G, Watanabe K, Ikeda Y.
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [Abstract] [Full Text] [Related]

  • 10. Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue.
    van Harmelen V, Wahrenberg H, Eriksson P, Arner P.
    Thromb Haemost; 2000 Feb; 83(2):304-8. PubMed ID: 10739390
    [Abstract] [Full Text] [Related]

  • 11. Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain.
    Martínez-Calatrava MJ, González-Sánchez JL, Zabena C, Martínez-Larrad MT, Luque-Otero M, Serrano-Ríos M.
    J Hypertens; 2007 Apr; 25(4):773-7. PubMed ID: 17351368
    [Abstract] [Full Text] [Related]

  • 12. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Jorgenson E, Deitcher SR, Cicek M, Liu X, Plummer S, Casey G, Witte JS.
    Prostate; 2007 Feb 01; 67(2):172-7. PubMed ID: 17044080
    [Abstract] [Full Text] [Related]

  • 13. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
    Grancha S, Estellés A, Tormo G, Falco C, Gilabert J, España F, Cano A, Segui R, Aznar J.
    Thromb Haemost; 1999 Apr 01; 81(4):516-21. PubMed ID: 10235431
    [Abstract] [Full Text] [Related]

  • 14. sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors.
    De Pergola G, Pannacciulli N, Coviello M, Scarangella A, Di Roma P, Caringella M, Venneri MT, Quaranta M, Giorgino R.
    Nutr Metab Cardiovasc Dis; 2008 Mar 01; 18(3):227-32. PubMed ID: 17400434
    [Abstract] [Full Text] [Related]

  • 15. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction.
    Fu L, Jin H, Song K, Zhang C, Shen J, Huang Y.
    Chin Med J (Engl); 2001 Mar 01; 114(3):266-9. PubMed ID: 11780311
    [Abstract] [Full Text] [Related]

  • 16. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects.
    Pannacciulli N, De Mitrio V, Marino R, Giorgino R, De Pergola G.
    Obes Res; 2002 Aug 01; 10(8):717-25. PubMed ID: 12181379
    [Abstract] [Full Text] [Related]

  • 17. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
    Castelló R, España F, Vázquez C, Fuster C, Almenar SM, Aznar J, Estellés A.
    Thromb Res; 2006 Aug 01; 117(5):487-92. PubMed ID: 15907980
    [Abstract] [Full Text] [Related]

  • 18. The role of proinflammatory cytokine gene polymorphisms for development of insulin resistance after renal transplantation.
    Gençtoy G, Kahraman S, Arici M, Altun B, Erdem Y, Bakkaloğlu M, Yasavul U, Turgan C.
    Transplant Proc; 2006 Mar 01; 38(2):521-8. PubMed ID: 16549165
    [Abstract] [Full Text] [Related]

  • 19. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.
    Mertens I, Ballaux D, Funahashi T, Matsuzawa Y, Van der Planken M, Verrijken A, Ruige JB, Van Gaal LF.
    Thromb Haemost; 2005 Dec 01; 94(6):1190-5. PubMed ID: 16411393
    [Abstract] [Full Text] [Related]

  • 20. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde.
    Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP.
    Thromb Haemost; 1995 Sep 01; 74(3):837-41. PubMed ID: 8571307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.